AI Summary

A significant disparity exists in the application of gene expression tests for breast cancer patients in the Netherlands. Only a third of eligible patients receive this test, which can help determine the most effective treatment approach. This limited use is particularly notable given the test's potential to prevent unnecessary chemotherapy. The introduction of reimbursement for the test has not led to a significant increase in its adoption, suggesting underlying barriers to its widespread implementation.

AI summaries can be wrong sometimes—always verify important details using the source article.